Overview

Putnam Associates provides strategy consulting for the life sciences sector, covering biopharmaceuticals, diagnostics, and medical devices, and also serves private equity and venture capital clients. It offers tailored, actionable strategic advice and analytical services to guide decisions across product and portfolio lifecycles. The firm differentiates itself through deep, exclusive life-sciences focus, global offices (Boston, San Francisco, New York, London), and long-term client relationships built on industry expertise. Its goal is to be a trusted partner that helps clients maximize value and navigate development, portfolio, and market-access challenges.

Simplify's Take

What believers are saying

• Bain & Company's 20% biotech headcount growth validates market demand for specialized consulting.
• ClearView's AI platform launch demonstrates client appetite for advanced analytics in biopharma strategy.
• Recent senior hires (Partner Iervolino, CPO Sulham, Ph.D. talent) strengthen leadership bench.

What critics are saying

• EU AI Act enforcement July 2026 requires certified AI capabilities Putnam lacks; existential threat.
• ClearView Healthcare's AI platform captures 15% biopharma strategy projects from existing clients.
• F.L. Putnam Investment Management brand confusion diverts life sciences consulting leads to wealth management.

What makes Putnam Associates unique

• Exclusive life sciences focus enables deep expertise across pharma, biotech, devices, diagnostics.
• Integrated service offerings through Inizio Advisory acquisitions: SmartAnalyst, PHMR, Creativ-Ceutical.
• 400+ professionals across 10 global offices serving 19 of top 20 pharma companies.

Help us improve and share your feedback! Did you find this helpful?

YesNo